Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENVB Enveric Biosciences	$1.26 -13.1%	$1.24	$1.01 ▼ $8.40	$4.10M	0.46	1.20 million shs	3.66 million shs
GTBP GT Biopharma	$0.97 -15.1%	$2.13	$0.96 ▼ $4.10	$3.44M	1.33	252,817 shs	191,150 shs
HXBM Helix BioMedix	$4.50	$5.60	$4.00 ▼ $6.45	$990K	0.51	36 shs	1 shs
TCRT Alaunos Therapeutics	$2.10 +11.1%	$3.41	$1.31 ▼ $6.20	$4.64M	-0.81	243,648 shs	78,424 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENVB Enveric Biosciences	+9.09%	+25.00%	+15.08%	+19.83%	-81.22%
GTBP GT Biopharma	0.00%	+5.56%	-45.71%	-58.70%	-49.11%
HXBM Helix BioMedix	0.00%	0.00%	-20.63%	-37.33%	-75.14%
TCRT Alaunos Therapeutics	+1.07%	-8.70%	-37.00%	-26.74%	-32.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENVB Enveric Biosciences	2.5 of 5 stars	3.5	2.0	0.0	0.0	4.4	0.0	0.6
GTBP GT Biopharma	2.741 of 5 stars	3.8	2.0	0.0	0.0	4.4	0.0	0.6
HXBM Helix BioMedix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	1.1433 of 5 stars	0.0	5.0	0.0	0.0	3.3	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENVB Enveric Biosciences	3.00	Buy	$10.00	693.65% Upside
GTBP GT Biopharma	3.50	Strong Buy	$11.00	1,037.07% Upside
HXBM Helix BioMedix	0.00	N/A	N/A	N/A
TCRT Alaunos Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	$0.67 per share	N/A
GTBP GT Biopharma	N/A	N/A	N/A	N/A	$0.80 per share	N/A
HXBM Helix BioMedix	N/A	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	$10K	464.10	N/A	N/A	$1.66 per share	1.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENVB Enveric Biosciences	-$9.57M	-$38.38	N/A	N/A	N/A	N/A	-341.48%	-240.71%	11/12/2025 (Estimated)
GTBP GT Biopharma	-$13.16M	-$4.07	N/A	N/A	N/A	N/A	-1,804.34%	-200.12%	11/13/2025 (Estimated)
HXBM Helix BioMedix	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	-$4.68M	-$2.46	N/A	∞	N/A	N/A	-168.02%	-121.37%	11/12/2025 (Estimated)

Latest HXBM, ENVB, GTBP, and TCRT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ENVB Enveric Biosciences	-$5.25	-$0.97	+$4.28	-$0.97	N/A	N/A
8/14/2025	Q2 2025	GTBP GT Biopharma	-$0.68	-$0.55	+$0.13	-$0.55	N/A	N/A
8/14/2025	Q2 2025	TCRT Alaunos Therapeutics	-$5.3340	-$0.63	+$4.7040	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	N/A
GTBP GT Biopharma	N/A	N/A	N/A	N/A	N/A
HXBM Helix BioMedix	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENVB Enveric Biosciences	N/A	2.42	2.42
GTBP GT Biopharma	N/A	2.76	2.76
HXBM Helix BioMedix	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	3.48	3.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENVB Enveric Biosciences	13.82%
GTBP GT Biopharma	8.15%
HXBM Helix BioMedix	N/A
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
ENVB Enveric Biosciences	1.10%
GTBP GT Biopharma	3.40%
HXBM Helix BioMedix	9.50%
TCRT Alaunos Therapeutics	16.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENVB Enveric Biosciences	20	3.25 million	3.21 million	Not Optionable
GTBP GT Biopharma	8	3.56 million	3.44 million	No Data
HXBM Helix BioMedix	8	220,000	204,000	Not Optionable
TCRT Alaunos Therapeutics	40	2.21 million	1.85 million	No Data

HXBM, ENVB, GTBP, and TCRT Headlines

Recent News About These Companies

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Sees Large Decline in Short Interest

August 18, 2025 | americanbankingnews.com

Alaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market Implications

August 12, 2025 | msn.com

Alaunos Therapeutics Appoints Holger Weis as New CEO

July 25, 2025 | theglobeandmail.com

Alaunos Therapeutics Taps Board Member Weis as Next CEO

July 2, 2025 | marketwatch.com

Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Alaunos Therapeutics Raises $850,000 in Private Offering

June 26, 2025 | tipranks.com

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - Morningstar

June 24, 2025 | morningstar.comM

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

June 23, 2025 | globenewswire.com

Alaunos Therapeutics Amends Warrant Agreement with Mast Hill

June 10, 2025 | tipranks.com

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

May 14, 2025 | globenewswire.com

Alaunos Therapeutics announces board member resignation

April 20, 2025 | investing.com

These 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?

April 7, 2025 | msn.com

Precigen Terminates License Agreement With Alaunos Therapeutics

October 11, 2024 | marketwatch.com

After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen

October 11, 2024 | fiercebiotech.comF

Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy

October 11, 2024 | finance.yahoo.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock, Short Interest Report

September 26, 2024 | benzinga.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock Quotes, Forecast and News Summary

September 26, 2024 | benzinga.com

Stella Pharma Corporation (4888.T) Stock Price, News, Quote & History - Yahoo Finance

September 24, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HXBM, ENVB, GTBP, and TCRT Company Descriptions

Enveric Biosciences NASDAQ:ENVB

$1.26 -0.19 (-13.10%)

Closing price 04:00 PM Eastern

Extended Trading

$1.22 -0.04 (-3.57%)

As of 05:44 PM Eastern

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

GT Biopharma NASDAQ:GTBP

$0.97 -0.17 (-15.14%)

Closing price 03:59 PM Eastern

Extended Trading

$0.96 -0.01 (-0.87%)

As of 05:42 PM Eastern

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Helix BioMedix OTCMKTS:HXBM

$4.50 0.00 (0.00%)

As of 08/22/2025

Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.

Alaunos Therapeutics NASDAQ:TCRT

$2.10 +0.21 (+11.11%)

Closing price 04:00 PM Eastern

Extended Trading

$2.05 -0.05 (-2.38%)

As of 04:23 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time